OrbiMed’s Scholar Rock SRRK Stock Holding History

OrbiMed’s Portfolio SRRK Stock Details SRRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$3.72M	–	127
2025 Q3	$3.72M	Buy	+100,000	New	+$3.5M	0.09%	94

Other funds holding SRRK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's SRRK Position: Q2 2025 in Review

OrbiMed sold out of Scholar Rock (SRRK) in Q2 2025, closing a stake of 151,800 shares — an estimated $4.88M sold.

OrbiMed first reported a position in SRRK in Q2 2022 and held it in 12 quarters. The position peaked at $79.8M in Q4 2023. 235 funds tracked by Wall St. Rank hold SRRK as of Q2 2025.

OrbiMed reported no remaining Scholar Rock position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 151,800 Scholar Rock shares in Q2 2025, an estimated $4.88M.
OrbiMed first reported a position in Scholar Rock in Q2 2022 and held it in 12 quarters.
OrbiMed's Scholar Rock position peaked at $79.8M in Q4 2023.
235 funds tracked by Wall St. Rank held Scholar Rock as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.